In 2005, de la Monte and Wands [13] proposed the concept of "type 3 diabetes" which postulates that AD is a neuroendocrine disorder associated with chronic deficits in insulin signaling that shares features with both T1D and T2D (insulin deficiency and resistance, respectively). The gene discussed is INS; the disease is type 2 diabetes mellitus.